Comparative Pharmacology
Head-to-head clinical analysis: APRESOLINE versus CONSENSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESOLINE versus CONSENSI.
APRESOLINE vs CONSENSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased peripheral resistance and blood pressure. The exact molecular mechanism is unclear but may involve interference with calcium movement or inhibition of inositol trisphosphate-induced calcium release.
Consensi is a fixed-dose combination of amlodipine, a dihydropyridine calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Celecoxib inhibits prostaglandin synthesis via COX-2, reducing inflammation and pain.
Initial: 10 mg oral 4 times daily for 2-4 days; increase to 25 mg 4 times daily for the first week. Maintenance: 50 mg 4 times daily; maximum 300 mg/day. IV: 20-40 mg IM or slow IV push, repeat as needed.
Adults: 0.25 mg/kg intravenously over 1 hour every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is 3-7 hours in patients with normal renal function; prolonged to 7-16 hours in renal impairment. Acetylator phenotype affects half-life: in slow acetylators, half-life may be 4-5 hours; in fast acetylators, 1-2 hours, but clinical effect (antihypertensive) lasts longer due to persistent binding to vascular tissue.
Terminal elimination half-life of 12-15 hours for parent drug and 18-24 hours for active metabolite, allowing once-daily dosing.
Primarily renal; 86-90% of an oral dose is excreted in urine as metabolites (N-acetylhydralazine, hydralazine pyruvic acid hydrazone) and unchanged drug (<10% unchanged); biliary/fecal excretion is minimal (<10%).
Primarily renal (70-80% as unchanged drug and active metabolite desmethyl-consensi); biliary/fecal: 15-20%.
Category C
Category C
Antihypertensive
Antihypertensive/NSAID Combination